|Day Low/High||2.28 / 2.41|
|52 Wk Low/High||0.24 / 0.65|
Patent Protection Extended until 2034
Patent Protection for RX-3117 Extended until 2036
Evidence of Prolonged Progression Free Survival in Pancreatic Cancer Patients Treated with RX-3117 and for Whom Three or More Prior Therapies had been Ineffective
RX-3117 is Currently in a Phase Ib/IIa Clinical Trial in Patients with Metastatic Pancreatic Cancer
Presents Clinical Data for Novel Targeted Cancer Therapeutics, RX-3117, Supinoxin™ and Archexin® at Prominent Oncology Conferences
Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer
Data Show RX-3117, Archexin® and Supinoxin™ Appear to be Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Show Early Evidence of Clinical Activity
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.